Abstract:Objectives Congenital Hypogonadotropic Hypogonadism (CHH) is among the few causes of male infertility, which could benefit from a rationale treatment. Both gonadotropin and GnRH therapy proved effective in inducing spermatogenesis in patients with CHH. However, due to the small sample size of the studies available and the lack of randomized studies, a precise evaluation of the efficacy and a comparison among different treatments remain difficult. A meta-analysis was conducted to evaluate the efficacy of either gonadotropin or GnRH treatment in inducing spermatogenesis in subjects with CHH and azoospermia and to identify possible treatment response moderators. Methods An extensive Medline and Embase search was performed, including the following words: "gonadotropins" or "GnRH", "infertility", "hypogonadotropic", "hypogonadism" and limited to studies in male humans. Results Overall, 41 and 22 studies were retrieved for gonadotropin and GnRH therapy in CHH patients, respectively. All considered the appearance of at least one spermatozoon in semen, whereas 23 and 9 considered sperm concentration upon gonadotropin and GnRH, respectively. The succes rate in obtaining at least one spermatozoon in the ejaculate and the achived sperm concentration were 0.70 [0.62-0.77] and 7.28 [5.19-9.36] x10^6/mL for gonadotropin therapy and 0.65 [0.52-0.77] and 6.48 [2.48-10.48] x10^6/mL for GnRH therapy. In studies using gonadotropins, worse results were obtained by hCG alone. Non differences were reported from studies using urinary-derived or recombinant FSH or from those enrolling or not patients previously treated with testosterone. Higher testis volume and lower LH and FSH at baseline were associated with a higher success rate upon gonadotropin therapy. Conclusions Gonadotropin therapy is a suitable option for inducing fertility in azoospermic CHH subjects. Protocols with combining FSH and hCG showed better results in terms of seminal outcomes than hCG therapy alone. These treatments appear to be more effective in subjects with lower baseline FSH and LH while previous TRT and FSH preparation do not affect the outcome. Conflicts of Interest The authors declare no conflict of interest.

The initiation and maintenance of gonadotropin-releasing hormone neuron identity in congenital hypogonadotropic hypogonadism

The Structure and Biological Functions of Gonadotropin-Releasing Hormone (Gnrh)

GNRHR-related central hypogonadism with spontaneous recovery – case report

Digenic Congenital Hypogonadotropic Hypogonadism Due to Heterozygous GNRH1 p.R31C and AMHR2 p.G445_L453del Variants

Mechanisms of Central Hypogonadism

Molecular genetics of isolated hypogonadotropic hypogonadism

Defective jagged-1 signaling affects GnRH development and contributes to congenital hypogonadotropic hypogonadism

Gonadotropin-releasing hormone neuronal migration

Current landscape of fertility induction in males with congenital hypogonadotropic hypogonadism

Control of puberty onset and fertility by gonadotropin-releasing hormone neurons

Analysis of genotype and phenotype in congenital hypogonadotropic hypogonadism with reversible gonadotropin deficiency: A case report

Digenic mutations account for variable phenotypes in idiopathic hypogonadotropic hypogonadism.

Developing neurites from mouse basal forebrain gonadotropin-releasing hormone neurons use Sonic hedgehog to modulate their growth

Mini-Puberty, Physiological and Disordered: Consequences, and Potential for Therapeutic Replacement

Congenital idiopathic hypogonadotropic hypogonadism: evidence of defects in the hypothalamus, pituitary, and testes

Successful pregnancy and delivery after ovulation induction therapy in a woman with congenital hypogonadotropic hypogonadism: a case report

(350) Efficacy And Predictors Of Spermatogenesis Induction Upon Gonadotropin And Gnrh Therapy In Congenital Hypogonadotropic Hypogonadism: A Meta-Analysis

GnRH-1 Neural Migration From the Nose to the Brain Is Independent From Slit2, Robo3 and NELL2 Signaling

CCDC141 Mutations in Idiopathic Hypogonadotropic Hypogonadism

In vitro cellular reprogramming to model gonad development and its disorders

Biochemical mechanism of pathogenesis of human gonadotropin-releasing hormone receptor mutants Thr104Ile and Tyr108Cys associated with familial hypogonadotropic hypogonadism